EHI
NBIX icon

Eagle Health Investments’s Neurocrine Biosciences NBIX Stock Holding History

Eagle Health Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-162,800
Closed -$23.1M – 33
2025
Q4 		$23.1M Hold
162,800
– – 5.07% 7
2025
Q3 		$22.9M Sell
162,800
-54,400
-25% -$7.37M 6% 6
2025
Q2 		$27.3M Sell
217,200
-7,900
-4% -$906K 6.74% 6
2025
Q1 		$24.9M Buy
225,100
+70,100
+45% +$8.88M 6.46% 7
2024
Q4 		$21.2M Buy
155,000
+26,400
+21% +$3.27M 5.19% 10
2024
Q3 		$14.8M Buy
+128,600
New +$17.6M 2.81% 15

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eagle Health Investments's NBIX Position: Q1 2026 in Review

Eagle Health Investments sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 162,800 shares — an estimated $23.1M sold.

Eagle Health Investments first reported a position in NBIX in Q3 2024 and held it in 6 quarters. The position peaked at $27.3M in Q2 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Eagle Health Investments reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Eagle Health Investments sold 162,800 Neurocrine Biosciences shares in Q1 2026, an estimated $23.1M.
  • Eagle Health Investments first reported a position in Neurocrine Biosciences in Q3 2024 and held it in 6 quarters.
  • Eagle Health Investments's Neurocrine Biosciences position peaked at $27.3M in Q2 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Eagle Health Investments's 13F filing for Q1 2026, filed 15 May 2026.